Nikolaidis NM, McCormack FX. Keratinocyte growth factor supports pulmonary innate immune defense through maintenance of alveolar antimicrobial protein levels and macrophage function.
PNEUMONIA ACCOUNTS for over one million hospital discharges each year and for ϳ5% of all inpatient hospital deaths (8, 17) . Although antibiotics typically speed recovery in bacterial pneumonias, even the most aggressive available therapies can fail to control virulent or resistant pathogens. Inadequate antimicrobial treatment is a leading cause of death for patients in the intensive care unit and predicts the development of lifethreatening acute lung injury in patients with pneumonia (18, 19) . The mortality and morbidity of serious respiratory infections could be substantially impacted by the development of broad-spectrum strategies that augment the innate immune defenses of the lung and enhance resistance to tissue injury.
Keratinocyte growth factor (KGF), also known as fibroblast growth factor 7 (FGF7), is an attractive candidate for this role. KGF is a potent epithelial mitogen and differentiation factor, produced almost exclusively by cells of mesenchymal origin, that acts predominantly on epithelial cells through ligation of an alternatively spliced tyrosine kinase receptor, FGF receptor 2 (FGFR2) type IIIb (7, 12, 30) . Exogenously administered KGF has been reported to protect the lungs of animals from a variety of subsequent insults, including acid instillation (44) , hyperoxia (25) , bleomycin (9) , radiation exposure (36, 46) , LPS instillation (14) , bacterial challenge (39) , and ventilatorinduced injury (40) . The protective effects of KGF have been linked to stimulation of alveolar type II epithelial cell (AECII) proliferation and differentiation, inhibition of apoptosis, attenuation of DNA damage, and induction of factors that reduce oxidative stress (11) . We recently reported that treatment with recombinant human KGF (rhKGF) results in release of granulocyte-macrophage colony-stimulating factor (GM-CSF) from the alveolar epithelium, leading to signal transducer and activator of transcription 5 (STAT5)-associated macrophage activation and enhanced clearance of Escherichia coli, Pseudomonas aeruginosa, and Mycobacterium tuberculosis from the murine lung (26, 43) . A recent study extended these findings to humans by demonstrating that bronchoalveolar lavage (BAL) fluid (BALF) isolated from rhKGF-challenged individuals enhances phagocytic uptake of bacteria by alveolar macrophages (AM) through a GM-CSF-dependent mechanism (32) . In addition, data from several laboratories indicate that KGF enhances expression of the pulmonary collectins surfactant protein (SP)-A and SP-D, proteins that bind and aggregate bacterial, fungal, and viral agents, directly activate macrophages, and enhance the phagocytosis and intracellular killing of a variety of pulmonary pathogens (16, 24) . We have found that SP-A and SP-D directly inhibit the growth of gramnegative bacteria by a membrane-destabilizing mechanism that is sensitive to pH, calcium concentration, and conditions that are hostile to protein structural integrity (e.g., heat or protease digestion) (23, 42) . Together, these studies suggest that KGF may have promise as a therapeutic agent that mitigates lung injury and enhances bacterial clearance in patients with pneumonia.
Although multiple laboratories have reported beneficial effects of exogenous KGF supplementation on protection and repair of epithelial tissues, there is little information on the natural role of endogenous KGF in lung injury and healing. Surprisingly, the phenotype described in the original KGF null mouse study revealed only an aberration in hair coat, with no gross alterations in lung morphology or epidermal wound healing (13) . Subsequent studies in KGF null mice revealed subtle effects of KGF deficiency, including reduced nephron number and kidney size (29) , thinned bladder urothelium (37) , impaired presynaptic differentiation and reduced seizure threshold (38) , reduced thymopoiesis following irradiation despite normal baseline thymic cellularity (2), delayed cutaneous wound contraction in a diabetic mouse background (27) , attenuated angiogenesis in a cutaneous wound model (28), depressed liver progenitor cell expansion and increased mortality in a model of toxin-induced hepatic injury (35) , and increased injury with delayed repair of mucosal tissue following dextran sulfate-induced colitis (6) . Overall, these studies suggest that endogenous KGF plays a role in regulating epithelial homeostasis and repair. Importantly, to our knowledge, no study has described a lung phenotype in the KGF null mouse, despite the critical role of respiratory epithelial cells in pulmonary function and host defense.
The purpose of the current study was to determine if endogenous KGF plays a role in the maintenance of innate defense against pulmonary infection. In KGF-deficient mice, we found delayed clearance of E. coli from the lungs, attenuated phagocytic function of AM, and reduced cell-free BALF antimicrobial activity that was associated with lower levels of alveolar SP-A, SP-D, and lysozyme. AECII counts and per cell gene expression of antimicrobial proteins were also reduced in KGF-deficient mice. These immune deficiencies in KGF knockout (KO) mice were largely rescued 3 days following a single intrapulmonary dose of rhKGF. We conclude that KGF supports alveolar innate immune defense through maintenance of alveolar antimicrobial protein levels and AM function.
MATERIALS AND METHODS
Mouse model and KGF treatment. All animal procedures were approved by the University of Cincinnati Institutional Animal Care and Use Committee. Mice were maintained under barrier containment in the vivarium facilities and appeared healthy and free of infection at the time of study. Age-matched female KGF wild-type (WT) and KO mice were generated by backcrossing hybrid B6;129-Fgf7 tm1Efu /J with WT C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME) through 10 generations. Heterozygous littermates from generation 10 were used to establish breeding pairs for generation of KGF WT and KO mice used in this study. In experiments in which rhKGF was used in a rescue scenario in mice, rhKGF/Kepivance (Swedish Orphan Biovitrium, Stockholm, Sweden) was delivered in a single dose [5 mg/kg intranasally (in)] in a 50-l volume. For terminal experiments, mice were euthanized by intraperitoneal injection of Fatal-Plus solution (Vortech Pharmaceuticals, Dearborn, MI).
Infection model and quantitative culture. E. coli K12 was grown in brain-heart infusion (BHI) broth overnight at 37°C with continuous agitation. On the following morning, bacteria were centrifuged, washed, and resuspended in PBS. Isoflurane-anesthetized mice were inoculated intranasally with 5 ϫ 10 6 colony-forming units (CFU) of E. coli in a 50-l volume. At 6 h postinfection, lungs were removed, homogenized, serially diluted, and plated on trypticase soy agar. After overnight incubation, manual plate counts were performed to quantify bacterial burden in the lung.
Whole lung and isolated AECII gene expression. Total RNA was isolated from murine lung tissue with RNAzol RT (Molecular Research Center, Cincinnati, OH) and used in 1-g aliquots to generate cDNA using the SuperScript III First-Strand Synthesis System (Life Technologies, Carlsbad, CA). Power SYBR Green PCR Master Mix (Applied Biosystems, Carlsbad, CA) was used to amplify DNA fragments through up to 40 cycles at 95°C for 15 s followed by 60°C for 1 min. Intron-spanning primers used in this study are described in Table 1 . Expression was determined relative to the housekeeping gene hypoxanthine guanine phosphoribosyl transferase. To quantify relative gene expression in ϳ2 ϫ 10 6 AECII isolated from individual mice, 100 ng of RNA were used for the conversion to cDNA.
Quantitation of AECII. The tracheas of euthanized mice were cannulated, and lungs were inflation-fixed with neutral buffered 10% formalin (Fisher Scientific, Fairlawn, NJ) at 25 cmH 2O. The lungs were immersed in neutral buffered 10% formalin overnight, embedded in paraffin, cut into 5-m sections, and mounted on adhesive microscope slides (TruBond 380, Tru Scientific, Bellingham, WA). 
Camp, cathelicidin; Csf2, granulocyte-macrophage colony-stimulating factor; Defb, ␤-defensin; Fgf7, fibroblast growth factor-7; Hprt, hyopxanthine phosphoribosyl transferase; Ltf, lactoferrin; Lyz1 and Lyz2, lysozymes 1 and 2; S100a8 and S100a9, calgranulins A and B; Sftpa, Sftpc, and Sftpd, surfactant proteins A, C, and D; Slpi, secretory leukocyte protease inhibitor; Splunc1, short plate, lung, and nasal epithelium clone 1.
AECII were identified by staining with an anti-pro-SP-C (SPC) antibody (Seven Hills Bioreagents, Cincinnati, OH). After antigen retrieval in citrate buffer, tissue sections were quenched with 0.3% hydrogen peroxide in methanol, blocked with 15% normal goat serum, and incubated with rabbit pro-SPC antibody (1:5,000 dilution) overnight at 4°C. Slides were developed by incubation with biotinlabeled goat anti-rabbit IgG secondary antibody (1:500 dilution) and avidin-peroxidase (Vector Laboratories, Burlingame, CA)-dependent oxidation of diaminobenzidine. A blinded quantitation of pro-SPCpositive cells per high-power field was performed at ϫ40 magnification on five random fields of lung parenchyma that were devoid of large airways or blood vessels.
Isolation of AECII. Lungs were perfused with 10 ml of sterile normal saline via the pulmonary artery. The airway was cannulated via tracheostomy with a 20-gauge metallic angiocatheter, and 3 ml (50 caseinolytic units/ml) of dispase (Corning, Corning, NY) were instilled followed by 0.5 ml of 1% low-melt agarose (warmed to 45°C). Lungs were rapidly cooled on ice for 2 min, incubated in 1 ml of dispase for 45 min at room temperature, and transferred to a culture dish containing DNase (100 U/ml; Worthington Biochemical, Lakewood, NJ). The parenchymal lung tissue was gently teased from the bronchi and homogenized. Cell suspensions were filtered, collected by centrifugation, and placed on prewashed 100-mm tissue culture plates coated with anti-mouse CD45 and CD32/16 antibodies (BD Biosciences, Franklin Lakes, NJ). After incubation for 60 min at 37°C in 5% CO 2 atmosphere to promote adherence of contaminating macrophages and fibroblasts, the AECII were gently panned from the plate, collected by centrifugation, and counted. Cell viability, determined by Trypan blue staining, was routinely Ͼ90%, and cell purity, determined by SP-C staining, was 75-90%.
BAL cell and fluid collection. BAL was performed by five cycles of infusion and aspiration using 1 ml of Hanks' balanced salt solution (HBSS), repeated five times. Recovery was routinely Ͼ80% of infused volume. BAL cells were separated from fluid by centrifugation at 400 g for 5 min at 4°C. Fluid from the first 1 ml of lavage was stored in a Ϫ80°C freezer until use, while cells recovered from all lavage cycles were combined and used immediately for assays. For some assays, BALF samples were concentrated using Centricon 3,000-mol-wt-cutoff spin filters (Millipore, Billerica, MA). Routine protein concentrations were determined with a bicinchoninic acid protein assay kit (Pierce Chemical, Rockford, IL), with bovine serum albumin (BSA) used as a standard.
Surfactant protein and cytokine concentration determination in BALF. SP-A and SP-D protein levels were quantified in BALF using a self-sandwich ELISA. Polyclonal rabbit anti-mouse SP-A and SP-D were generated against recombinant antigens. ELISAs were performed by loading equivalent volumes of BALF from each mouse into wells of a microplate precoated with 10 g/ml anti-mouse SP-A or SP-D antibody. After the samples were incubated and washed, horseradish peroxidase-conjugated anti-mouse SP-A or SP-D secondary antibody was added, and the mixture was incubated at room temperature. After the samples were washed, the assays were developed by incubation with SureBlue Reserve TMB Microwell Peroxidase Substrate (KPL, Gaithersburg, MD) and measured at a wavelength of 450 nm. Recombinant mouse SP-A and SP-D were used to generate standard curves. Cytokine and chemokine concentrations were determined in BALF using commercial ELISAs (R & D Systems, Minneapolis, MN).
Lysozyme activity assay. Lysozyme activity was quantified in BALF according to published methods with minor modifications (21) . Briefly, Micrococcus luteus (Sigma-Aldrich, St. Louis, MO) was suspended in 0.4 M potassium phosphate buffer (32% dibasic-68% monobasic, pH 6.5 at 25°C) containing 0.1% sodium azide and 0.1% BSA. A 20-l aliquot of BALF was mixed with a 180-l aliquot of the M. luteus suspension pretitrated to result in an ultimate optical density (OD) at 450 nm (OD450nm) of 1.0 for the mixture. Changes in absorbance readings were recorded every 4 min during incubation at 37°C in a VICTOR microplate reader (Perkin Elmer, Waltham, MA). Wells containing purified chicken lysozyme (Worthington Biochemical) and wells containing assay buffer alone were used as positive and negative controls, respectively. Lysozyme activity was calculated as ⌬OD450nm ϭ (buffer OD450nm Ϫ sample OD450nm) over the linear range of the curve.
Bacterial killing assay. E. coli K12 was grown overnight in BHI broth at 37°C with continuous agitation. On the following morning, bacteria were subcultured in fresh medium for 3 h, and log-phase organisms were harvested by centrifugation, washed, and resuspended in HBSS. For assessment of BALF antimicrobial activity, 90 l of BALF and 10 l (5 ϫ 10 3 CFU) of the E. coli suspension were mixed into wells of a 96-well microtiter plate and then incubated at 37°C with constant agitation for 90 min. Bacteria were disaggregated by vigorous discharge through a pipette, diluted, and plated on trypticase soy agar plates. After overnight incubation of the plates at 37°C, CFU were counted.
Bacterial viability assay. Bacterial viability was assessed by incubation of 2 ϫ 10 6 CFU of E. coli in 100 l of BALF (200 g/ml) for 30 min followed by addition of the fluorescent probe SYTO 9, which stains the bacterial membrane green regardless of viability state, and propidium iodide, which stains DNA red in permeabilized (dead) cells (BacLight, Life Technologies, Grand Island, NY), as previously described (3). To determine the percent viability, live (green) and dead (red) cells were quantified on a VICTOR fluorescence microplate reader (Perkin Elmer) by comparing fluorescence at 485 and 530 nm with that of a five-point standard curve generated by mixing varying proportions of ethanol-killed E. coli and live E. coli prior to staining.
Bacterial permeability assay. E. coli were grown to mid-log phase in BHI broth at 37°C, washed twice with 5 mM Tris and 150 mM NaCl, and resuspended to OD at 600 nm of 1.0. A 50-l volume of the E. coli suspension was aliquoted into a 96-well polystyrene microtiter plate and incubated in concentrated BALF (450 g/ml) for 15 min at 37°C with constant agitation. The cleavage-activated alkaline phosphatase substrate ELF 97 (Life Technologies) was added, and fluorescence was measured over time at excitation and emission wavelengths of 355 and 535 nm, respectively (20).
Phagocytosis assay. The E. coli K12 isolate was labeled with pHrodo Red, succinimidyl ester (Life Technologies) according to the manufacturer's instructions. Labeled bacteria were preopsonized and incubated for 30 min at 37°C with freshly isolated BAL cells at 200 bacteria/cell in HBSS supplemented with 10 mM HEPES and 10% normal mouse serum. After incubation, cells were washed twice in ice-cold HBSS with 10 mM HEPES and 0.2% BSA and placed on ice. Nonspecific binding was blocked with 2 l of Fc Block (BD Biosciences) and 5 l of rat serum per 100-l sample for 10 min before the cells were stained with eFluor 660 F4/80 (clone BM8), eFluor 450 CD11b (clone M1/70), and peridinin chlorophyll (PerCP) eFluor 710 CD11c (clone N418) for 30 min. All antibodies were purchased from eBioscience (San Diego, CA). After they were washed, the samples were run on a BD LSRII flow cytometer using fluorescence-minusone controls to correct for spectral overlap. Unlabeled bacteria served as a negative control for pHrodo Red fluorescence. Median channel fluorescence of pHrodo Red was used as the measure of phagocytosis for F4/80 ϩ , CD11c ϩ , and CD11b Ϫ /low AM. BAL and blood cell composition determination. BAL cells were suspended in 100 l of ice-cold buffer for flow cytometry (PBS, 1% BSA, and 0.1% sodium azide). Nonspecific binding was blocked by addition of 5 l of rat serum and 1 g of anti-mouse CD16/32 (BD Biosciences, San Diego, CA) to the suspension for 15 min. The cells were then stained with anti-mouse CD45, F4/80, CD11c, CD3, CD45R/B220, and Ly6G (BD Biosciences or Affymetrix, San Diego, CA) for 30 min. Samples were run on a BD LSRII flow cytometer using fluorescence-minus-one controls and analyzed with FCS Express 5 software (Denovo Software, Los Angeles, CA). BAL cells were identified by the profile of antibody staining as AM (CD45 ϩ ,
. Absolute BAL leukocyte numbers were calculated by multiplying total BAL cell counts by the percentage of cells in each subpopulation (e.g., macrophage and monocyte) as determined by flow cytometry. Blood was collected by cardiac puncture in EDTA-coated tubes, and cellular composition was determined using an automated system (Hemavet 950, Drew Scientific, Miami Lakes, FL).
Statistics. Statistical analysis was performed using GraphPad Prism 5. Significance between two groups was determined with the Student's t-test. In experiments where more than two groups were compared, an ANOVA and Bonferroni's posttest comparing selected groups (i.e., WT vs. KO and KO vs. KO ϩ rhKGF) were employed to correct for multiple comparisons. Significant differences were determined at P Ͻ 0.05.
RESULTS

Pulmonary bacterial clearance is impaired in KGF KO mice in association with reduced antimicrobial activity in alveolar lining fluid and reduced phagocytic function of AM.
To test the role of endogenous KGF in the response to pulmonary infectious challenge, KGF WT and KO mice were inoculated intranasally with 5 ϫ 10 6 CFU of E. coli. The lungs were harvested 6 h postchallenge, homogenized, and plated on agar. Mean bacterial burden was threefold higher in lungs of KGF KO than WT mice (1.1 ϫ 10 7 vs. 3.7 ϫ 10 6 CFU/lung, P Ͻ 0.01; Fig. 1A ). To investigate mechanisms responsible for the bacterial clearance defect in KGF KO mice, we performed BAL on uninfected KGF WT and KO mice to collect BALF and cells for in vitro bacterial clearance assays. Antimicrobial activity was reduced in BALF isolated from KGF KO mice, allowing approximately twofold more E. coli growth than in BALF isolated from KGF WT mice (3.9 ϫ 10 4 vs. 2.0 ϫ 10 4 CFU, P Ͻ 0.01) during a 90-min incubation period (Fig. 1B) . Phagocytic function was reduced by more than threefold in AM isolated from KGF KO compared with WT mice [922 vs. 3,000 median fluorescence intensity (MFI), P Ͻ 0.01; Fig. 1C ]. Together, these results indicate that pulmonary bacterial clearance in KGF KO mice is impaired and is associated with reduced alveolar lining fluid antimicrobial activity and AM function.
Leukocyte recruitment and the inflammatory response are not impaired in KGF KO mice. To determine if the bacterial clearance defect in KGF KO mice was associated with altered inflammatory cell recruitment to the lung, we quantified blood and BAL leukocytes prior to infection and 6 h after intranasal inoculation with 5 ϫ 10 6 CFU of E. coli. Blood leukocyte composition was similar in KGF WT and KO mice prior to infection, and neutrophilia occurred in both groups following bacterial challenge, as expected. Although the number of circulating neutrophils following infection tended to be higher in KGF KO mice, the levels did not reach statistical significance ( Fig. 2A) . BAL leukocyte counts were similar in KGF WT and KO mice prior to infection, and neutrophil counts were marginally higher in KGF KO mice postchallenge (1.4 ϫ 10 6 Ϯ 1.7 ϫ 10 5 and 9.6 ϫ 10 5 Ϯ 4.2 ϫ 10 4 neutrophils in KO and WT mice, respectively, P Ͻ 0.05; Fig. 2B ). To assess potential differences in the inflammatory tone of the lungs of KGF WT and KO mice, we assessed proinflammatory chemokines and cytokines, including CXCL1/KC, GM-CSF, TNF␣, and IL-6, in BALF before and after infection. These mediators were below detectable limits in BALF from both groups prior to infection (data not shown) and increased similarly in KGF WT and KO mice following infection (Fig. 2C) . Collectively, these data indicate that leukocyte recruitment and the inflammatory responses are not significantly altered in KGF KO mice, suggesting that deficits in antimicrobial proteins and AM function are likely the primary mechanisms responsible for the bacterial clearance defect in KGF KO mice.
Whole lung expression of the antimicrobial collectins and lysozyme genes is selectively reduced in KGF KO mice. Whole lung gene expression was analyzed to determine if deficiencies in specific innate immune mediators were associated with the bacterial clearance defect in KGF KO mice (Fig. 3) . Fgf7 was not detected in the KGF KO mice. Whole lung expression of Csf2 (GM-CSF) was not different between groups. Expression of Sftpc (SP-C), which is restricted to AECII, was reduced by 25% in lungs of KGF KO compared with WT mice (393 Ϯ 16 and 527 Ϯ 25 in KO and WT, respectively, P Ͻ 0.01). Whole lung expression of the antimicrobial proteins Sftpa (SP-A), Sftpd (SP-D), Lyz1 (lysozyme 1), and Lyz2 (lysozyme 2) was also reduced in KGF KO compared with WT mice: Sftpa by 39% (36 Ϯ 1.4 and 59 Ϯ 2.7 in KO and WT, respectively, P Ͻ 0.01), Sftpd by 36% (7.3 Ϯ 0.5 and 11.4 Ϯ 0.8 in KO and WT, respectively, P Ͻ 0.01), Lyz1 by 49% (2.3 Ϯ 0.2 and 4.5 Ϯ 0.4 in KO and WT, respectively, P Ͻ 0.01), and Lyz2 by 31% (81 Ϯ 3.2 and 116 Ϯ 5.4 in KO and WT, respectively, P Ͻ 0.01). Expression of genes for other antimicrobial proteins tested, including Slpi (secretory leukocyte protease inhibitor), Ltf (lactoferrin), Defb1 (␤-defensin 1), Camp (cathelicidin), Splunc1 (short plate, lung, and nasal epithelium clone 1), S100a8 (calgranulin A), and S100a9 (calgranulin B), was not different in KGF KO compared with WT mice. Defb2 (␤-defensin 2), Defb3 (␤-defensin 3), and Defb4 (␤-defensin 4) were not detected in either group (data not shown). Together these results indicate that expression of the antimicrobial collectins SP-A and SP-D, as well as the two forms of lysozyme found in mice, is selectively reduced in the absence of endogenous KGF. The concurrent reduction in Sftpc expression suggests that deficits may be attributable to changes in AECII numbers or per cell gene expression or both in the absence of endogenous KGF.
Antimicrobial collectin and lysozyme protein levels are reduced in alveolar lining fluid of KGF KO mice. Collectin and lysozyme protein concentrations were assessed in BALF isolated from KGF WT and KO mice to determine if the changes in gene expression in KGF KO mice were reflected at the protein level. In KGF KO mice, SP-A levels were decreased by 20% (2.4 Ϯ 0.2 and 3.0 Ϯ 0.2 g/ml in KO and WT, respectively, P Ͻ 0.05) and SP-D levels were decreased by 39% (0.85 Ϯ 0.08 and 1.36 Ϯ 0.07 g/ml in KO and WT, respectively, P Ͻ 0.01; Fig. 4, A and B) . Lysozyme levels in BALF, quantified by a turbidimetric activity assay using M. luteus as the substrate, were also reduced by 18% in KGF KO compared with KGF WT mice (0.42 Ϯ 0.01 vs. 0.51 Ϯ 0.02 OD, P Ͻ 0.01; Fig. 4C ). These results demonstrate that impaired bacterial clearance and reduced antimicrobial activity in the alveolar lining fluid of KGF KO mice are associated with reductions in alveolar levels of SP-A, SP-D, and lysozyme, suggesting a possible causal relationship.
AECII counts and antimicrobial gene expression are reduced in KGF KO mice. Reduction of whole lung expression of Sftpc in KGF KO mice raises the following question: Is the deficiency of antimicrobial collectins and lysozyme in the alveolar lining fluid due to reduction in AECII cell numbers or per cell gene expression or both? We therefore assessed AECII numbers by morphometric analysis and measured relative gene expression in isolated AECII. A representative image of KGF WT and KO mouse lung sections incubated with anti-pro SPC IgG linked to horseradish peroxidase shows staining of pro-SPC-positive AECII cells following avidin-peroxidase-dependent oxidation of diaminobenzidine (Fig. 5A) . Counts of pro-SPC-positive cells per high-power field were reduced by 17% in KGF KO compared with WT mice (11.5 Ϯ 0.5 vs. 13.8 Ϯ 0.8, P Ͻ 0.01; Fig. 5B ). Relative expression of surfactant protein and lysozyme genes in isolated AECII tended to reflect the magnitude of differences in expression that we found in whole lung homogenates (Fig. 5C ). Relative expression of Sftpd was reduced by 37% (27.7 Ϯ 2.1 and 43.9 Ϯ 4.4 in KO and WT, respectively, P Ͻ 0.01), Lyz1 by 48% (10.9 Ϯ 0.9 and 21.1 Ϯ 4.0 in KO and WT, respectively, P Ͻ 0.05), and Lyz2 by 44% (161 Ϯ 7 and 242 Ϯ 17 in KO and WT, respectively, P Ͻ 0.01) in AECII isolated from KGF KO compared with KGF WT mice. The magnitude of these differences in gene expression exceeds the reductions that would have been predicted based on 17% lower AECII counts in the KO mice. Trends toward reductions in Sftpc and Sftpa gene expression on a per cell basis in the KO vs. WT mice did not reach statistical significance. These data suggest that endogenous KGF supports both maintenance of AECII cell numbers and differentiated expression of genes that encode antimicrobial proteins.
Reduced levels of antimicrobial collectins and lysozyme in KGF KO mice are at least partially restored by rhKGF. To determine if the deficiency of antimicrobial collectins and lysozyme in KGF KO mice could be rescued by administration of exogenous KGF, we treated mice with a single dose (5 mg/kg in) of rhKGF. Control KGF WT and KO mice were treated with PBS vehicle alone by the same route. BALF was collected from each group 3 days after rhKGF treatment. SP-A levels were lower in BALF isolated from vehicle-treated KGF KO than vehicle-treated WT mice (0.8 Ϯ 0.1 vs. 2.5 Ϯ 0.5 g/ml, P Ͻ 0.01), and the trend toward partial correction of BALF SP-A levels in KGF-treated KO mice did not reach statistical significance (Fig. 6A) . SP-D levels were also lower in BALF isolated from vehicle-treated KGF KO than vehicletreated WT mice (0.6 Ϯ 0.04 vs. 1.3 Ϯ 0.08 g/ml, P Ͻ 0.01), and supranormal SP-D levels were induced following KGF treatment (0.6 Ϯ 0.04 and 4.0 Ϯ 0.02 g/ml in KO and KO ϩ KGF, respectively, P Ͻ 0.01; Fig. 6B ). Similar to SP-A, lysozyme levels were significantly lower in BALF isolated from vehicle-treated KGF KO than vehicle-treated WT mice (0.29 Ϯ 0.03 vs. 0.47 Ϯ 0.02 OD, P Ͻ 0.01), and treatment of KO mice with KGF resulted in a partial increase in lysozyme levels that did not achieve statistical significance (Fig. 6C ). These results demonstrate that SP-D deficiency in KGF KO mice can be rescued by exogenous administration of KGF.
The pulmonary bacterial clearance defect in KGF KO mice is rescued by exogenous KGF. To determine if the defect in pulmonary bacterial clearance in KGF KO mice could be rescued by administration of exogenous KGF, we treated mice with a single dose (5 mg/kg in) of rhKGF. Control KGF WT and KO mice were treated with PBS vehicle alone by the same route. At 3 days after treatment, mice were lavaged to separately assess the antimicrobial activities of the soluble and Fig. 3 . Whole lung expression of the antimicrobial collectins and lysozyme genes are differentially reduced in KGF KO mice. Lungs were harvested from KGF WT and KO mice, and whole lung gene expression for 14 antimicrobial proteins was determined on lung homogenates by RT-PCR and normalized to expression of the housekeeping gene hypoxanthine guanine phosphoribosyl transferase. Values are means Ϯ SE (n ϭ 5-6 mice/group). **P Ͻ 0.01. ND, not detected. Fgf7, fibroblast growth factor-7; Csf2, GM-CSF; Sftpc, Sftpa, and Sftpd, surfactant proteins C, A, and D; Lyz1 and Lyz2, lysozymes 1 and 2; Slpi, secretory leukocyte protease inhibitor; Ltf, lactoferrin; Defb1, ␤-defensin 1; Camp, cathelicidin; Splunc1, short plate, lung, and nasal epithelium clone 1; S100a8 and S100a9, calgranulins A and B. cellular alveolar compartments or inoculated with bacteria intranasally to assess in vivo clearance. At 6 h after intranasal inoculation of 5 ϫ 10 6 CFU of E. coli, the bacterial burden was more than threefold higher in the homogenized lungs of vehicle-treated KGF KO than vehicle-treated WT mice (1.7 ϫ 10 7 vs. 5.3 ϫ 10 6 CFU, P Ͻ 0.01), and the clearance defect was reversed by treatment of KO mice with KGF (1.7 ϫ 10 7 and 6.1 ϫ 10 6 CFU for KO and KO ϩ KGF, respectively, P Ͻ 0.01; Fig. 7A ). BALF isolated from vehicle-treated KGF KO mice exhibited reduced antimicrobial activity, allowing approximately twofold more growth than in BALF isolated from vehicle-treated WT mice (2.9 ϫ 10 4 and 1.5 ϫ 10 4 CFU for KO and WT, respectively, P Ͻ 0.01) over a 90-min incubation period, while BALF antimicrobial activity was restored in KO mice treated with KGF (2.9 ϫ 10 4 and 9.0 ϫ 10 3 CFU for KO and KO ϩ KGF, respectively P Ͻ 0.01; Fig. 7B ). To control for the possibility that rhKGF could have intrinsic antimicrobial activity, BALF from KGF KO mice was spiked with 100 g of rhKGF or vehicle alone prior to the bacterial killing assay. Identical colony counts from rhKGF and vehicle-spiked BALF demonstrated that even if 100% of the instilled rhKGF was recovered in lavage at 3 days after instillation, bacterial killing would not be affected by any putative direct antimicrobial effects of KGF itself (data not shown). Exposure of E. coli to BALF isolated from vehicle-treated WT or KGF-treated KO mice resulted in a 30% reduction in bacterial viability relative to BALF isolated from vehicle-treated KO mice (71 Ϯ 5% or 71 Ϯ 3% viability for WT or KO ϩ rhKGF, respectively, vs. 100 Ϯ 7% viability for KO, P Ͻ 0.01; Fig. 7C ). Bacterial permeabilizing activity was nearly threefold lower in BALF isolated from vehicle-treated KGF KO than vehicle-treated WT mice (133 Ϯ 31 vs. 366 Ϯ 65 arbitrary units); however, the partial restoration of permeabilizing activity in BALF isolated from KGF-treated KO mice did not reach statistical significance (Fig. 7D) . Finally, phagocytic function was more than threefold lower in AM isolated from vehicle-treated KGF KO than vehicle-treated WT or KGF-treated KO mice (972 Ϯ 199 MFI for KO vs. 2,851 Ϯ 627 or 2,837 Ϯ 484 MFI for WT or KO ϩ rhKGF, respectively, P Ͻ 0.05; Fig. 7E ). Together, these data demonstrate that the pulmonary bacterial clearance defect, the deficiency of alveolar lining fluid antimicrobial activity, and the reduced phagocytic function of AM in KGF KO mice can largely be reversed by exogenously delivered KGF.
DISCUSSION
KGF is a well-characterized pulmonary epithelial mitogen and differentiation factor, but relatively little is known about its role in host defense. Our prior studies demonstrated that rhKGF treatment results in release of GM-CSF from the alveolar epithelium, leading to STAT5-associated macrophage activation and enhanced clearance of E. coli, P. aeruginosa, and M. tuberculosis from the murine lung (26, 43) . Exogenously delivered KGF is also known to induce secretion of the pulmonary collectins (45), surfactant-associated proteins that have well-characterized host defense properties (24) . Based on this information, we postulated that endogenous KGF deficiency would result in impaired pulmonary innate immune function.
To explore this hypothesis, we studied KGF KO animals that were developed by breeding the KGF null allele through 10 generations into the C57BL/6 background to eliminate subtle immune differences between littermates attributable to genetic variations. We found that KGF deficiency resulted in a defect in bacterial clearance, an attenuation of AM phagocytic function, and a reduction in the killing and permeabilizing activity of the alveolar lining fluid, which were largely rescued 3 days following a single intrapulmonary dose of rhKGF. Our data suggest that reduction of antimicrobial activity in BALF collected from KGF KO animals is at least partially attributable to decreased pulmonary collectin and lysozyme expression, deficiencies that are likely related to reduction of AECII numbers and differentiated AECII functions. The antimicrobial functions of collectins and lysozyme have been previously validated in mouse models of excess and deficiency (1, 22, 42) . Our results also demonstrate that bacterial permeabilization activity is reduced in KGF KO BALF, a finding that is consistent with the known antimicrobial mechanisms of col- lectins and lysozyme (15, 42) . It is possible and perhaps likely that other antimicrobial proteins are playing a role in the BALF permeabilizing and killing defects, but we did not find any other differences from WT mice in expression of the antimicrobial protein genes tested. It is also possible that small reductions in collectins and lysozymes may interfere with cooperative interactions with other antimicrobial proteins. Synergistic killing of E. coli has been demonstrated for lysozyme in combination with other antimicrobial factors, including lactoferrin and secretory leukocyte protease inhibitor (33) . We conclude that the concurrent reduction of collectins and lysozyme negatively impacts antimicrobial activity within alveolar lining fluid, through loss of their individual contributions to bacterial killing and, perhaps, through loss of cooperative interactions with other antimicrobial partners. A limitation of this study is that the relative physiological importance of the collectins and lysozyme in host defense activities of KGF KO and exogenously supplemented models remains incompletely defined. In addition, this study cannot exclude the possibility that other antimicrobial peptides, such as defensins or cathelicidin, are induced by rhKGF and contribute to the rescue of alveolar lining fluid antimicrobial activity in KGF KO animals. Finally, the relative role of the AM in altered bacterial clearance and the mechanisms of attenuated AM phagocytic function in KGF KO animals remain to be determined. We demonstrated that, other than a mild BAL neutrophilia in the KGF KO animal after bacterial challenge, there were no meaningful between-group differences in selected inflammatory mediators or inflammatory cell numbers or composition, either at baseline or 6 h after intratracheal E. coli delivery. It is notable that, in our prior studies (26, 43) and those of others (32) , KGF supplementation enhanced GM-CSF levels. It is curious therefore that we did not detect any difference in whole lung GM-CSF gene expression prior to infection or in postinfection BALF GM-CSF protein levels. BALF GM-CSF protein levels in unchallenged animals are at or below the limits of detection by ELISA; therefore, it is difficult or impossible to measure reductions in BAL GM-CSF protein levels in the KGF KO animals via available methods. To overcome these limitations, our ongoing studies to explore the mechanism of attenuated AM function in KGF KO animals are focused on AM transcription. These preliminary data suggest that there are no significant between-group baseline differences in M1 or M2 macrophage phenotypes, based on expression of markers such as arginase-1, inducible nitric oxide synthase, and IL-10, but do provide some evidence of decreased GM-CSF-dependent transcript expression (data not shown) in the KGF KO animals relative to WT controls. Further study is required to definitively determine if altered GM-CSF expression plays a role in the immune defects in the KGF KO mouse model. Despite these limitations, our study validates a role for KGF in the maintenance of AECII pool sizes and differentiated AECII functions that support pulmonary host defense. Nature often borrows elements of normal developmental processes to execute repair and host defense functions in the mature organism (41) . Examples include the key roles of NFB pathway proteins in Drosophila morphogenesis and in inflammation in mammalian organisms. KGF is a potent epithelial mitogen with well-described cytoprotective and regenerative properties (11) . Reports that KGF is upregulated in gingival fibroblasts by LPS and inflammatory cytokines (IL-1␣, IL-1␤, IL-6, TNF␣, TGF␣, and platelet-derived growth factor-BB) (4, 5, 31) and that KGF stimulates the production of antimicrobial peptides and enhances bactericidal activity of skin grafts by Ͼ500-fold (10) are consistent with a role for the growth factor in the augmentation of innate immune defenses. Viget et al. (39) reported that a single intratracheal instillation of KGF (5 mg/kg) in rats 48 h prior to infection with P. aeruginosa improved barrier function in vivo and in isolated perfused lungs, enhanced bacterial clearance, and increased survival. The documented efficacy of KGF in reducing the severity of mucositis following radiation and chemotherapy illustrates the protective potential of KGF for epithelial and mucosal tissues (34) . Although the mechanism of beneficial KGF actions in mucositis is widely attributed to preservation of epithelial barrier integrity, infection is central to the pathogenesis of the condition, and we speculate that the antimicrobial actions of KGF might have also contributed to the favorable outcomes of the mucositis studies that led to US Food and Drug Administration approval for that indication.
Collectively, these data are consistent with a previously undefined role for endogenous KGF in the maintenance of alveolar epithelial homeostasis and pulmonary innate immunity. In conjunction with our prior studies, our most current results suggest that KGF may enhance bacterial clearance through a dual mechanism that includes augmentation of mac- rophage antimicrobial actions and maintenance of antimicrobial protein levels in the alveolar lining fluid. KGF maintains AECII in vivo and in pharmacological concentrations induces them to proliferate and release antimicrobial proteins and GM-CSF, augmenting the permeabilizing, aggregating, and killing activities of the alveolar lining fluid and enhancing the recruitment, oxidant, and killing functions of AM. We submit that pharmacological augmentation of antimicrobial protein production and macrophage activation through a KGF/FGFR2-IIIb/GM-CSF/GM-CSF receptor paracrine loop might be exploited to advantage to enhance the host defense functions in the air space. Although the magnitude of the effect of KGF on bacterial clearance in this model is modest relative to standard treatments, the combination of antibiotic therapy with pharmacological augmentation of endogenous innate immune defense is an intuitively appealing treatment approach that may prove to be additive or even synergistic.
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No conflicts of interest, financial or otherwise, are declared by the authors. Fig. 7 . Rescue of the pulmonary bacterial clearance defect in KGF KO mice following a single dose of rhKGF. KGF KO mice were treated with a single dose of rhKGF (5 mg/kg in). Control KGF WT and KO mice were treated with PBS vehicle alone by the same route. At 3 days after treatment, mice were inoculated with bacteria to assess in vivo clearance or BAL was performed to collect cells and fluid for in vitro assays. A: in vivo pulmonary bacterial clearance assessed by quantitative culture of homogenized lung tissue 6 h after intranasal inoculation with 5 ϫ 10 6 CFU of E. coli. B: antimicrobial activity of alveolar lining fluid. E. coli (5 ϫ 10 3 CFU) was mixed with BALF in wells of a microplate. After 90 min of incubation at 37°C, suspensions were plated, and antimicrobial activity was determined following overnight growth. C: bacterial viability assessed with the BacLight Live/Dead staining kit after incubation of 2 ϫ 10 6 CFU of E. coli in BALF (200 g/ml) at 37°C with shaking for 30 min. D: permeabilizing activity of concentrated BALF (450 g/ml) assessed by incubation of E. coli in the presence of the impermeant alkaline phosphate substrate ELF 97 and use of fluorescence expressed as arbitrary units (au) to quantify permeabilization of the bacterial membrane. E: phagocytic function of alveolar macrophages. Harvested BAL cells were incubated with pHrodo-labeled bacteria in a 1:200 ratio for 30 min at 37°C. MFI of pHrodo in alveolar macrophages was determined by flow cytometry and used as a measure of the number of E. coli per cell. *P Ͻ 0.05, **P Ͻ 0.01.
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